Webinar: Strategic Pharmacovigilance Activities. Scalable and Tailor-made Outsourcing Models
Larger companies often limit their strategic pharmacovigilance activities outsourcing only to highly manual and repetitive tasks, while the smaller ones may want to outsource their entire pharmacovigilance system. But is there anything in between?
- How can larger companies benefit from outsourcing strategic pharmacovigilance activities while maintaining full control and compliance?
- How can small/medium-sized companies get access to a serious pharmacovigilance database that grows with them without having to break the bank?
- What are the advantages of scalable and tailor-made outsourcing models?
- How can the pharmaceutical companies obtain benefits from the scalability and standardization required to ensure central oversight while also retaining local effectiveness?
You will learn about strategic pharmacovigilance activities outsourcing through scalable and tailor-made outsourcing models and how it can be done in a controlled way:
1. Full pharmacovigilance outsourcing
- What does it mean?
- How will you remain in control?
2. Outsourcing a pharmacovigilance database
- How to select a proper database?
- How to get access to it without buying it yourself?
- What control levels can you opt for?
3. Outsourcing specific strategic pharmacovigilance activities
- How to remain in control?
Optimizing your pharmacovigilance activities?
Make use of our experts’ invaluable know-how in managing pharmacovigilance activities while remaining in control.
Who should attend?
- Global QPPVs / Deputies
- QPPV Office managers
- Heads of Pharmacovigilance
- Heads of Pharmacovigilance Technologies
- Drug Safety Managers
- Drug Safety Leaders involved in Risk Management, Aggregate Safety reports, Oversight and Standards
Duration: 50 min.
Speakers:
- Head of Global Pharmacovigilance, Martijn van de Leur;
- International QPPV, Olga Asimaki;
- QPO Manager and Head of Pharmacovigilance Technologies, Gediminas Zvicevičius.
Martijn van de Leur, MSc
Head of Global Pharmacovigilance
Other content that might interest you:
CMC: Down the road in effective IND/IMPD writing
In the previous two articles, we have shared our experience on various aspects of effective IND/IMPD CMC writing, considering proper planning, assigning a dedicated CMC writing team, and having effective project management. In addition, we discussed technical writing particulars giving some key messages on document preparation. Now, we will discuss other important points. These are safety, data completeness, and geographical regions.
Proper Publicizing in CEECs – Path to Successful Social Media Commercials
With the growth of social media network users all over the world, there is no doubt that one of the most widely used channels for promoting is social media. Statistics show that Facebook and Instagram were used actively with more than 3.4 billion people daily by January 2020. Therefore, since medical devices and over-the-counter medicines are being more often promoted by commercials on social media nowadays, there is a greater risk of hidden or misleading advertisements.
How Mergers and Acquisitions of Pharma Companies affect Regulatory Affairs?
It is easy to notice that Mergers and Acquisitions (M&A) have become a frequent occurrence in the Pharmaceutical industry, especially during the previous decades. Pharma industry is one of the leading industries in the number of M&A and the size of investments for such transitions. The value for M&A in the pharmaceutical sector was $221 billion in the first half of the year 2015. In 2019, the worth of pharma companies M&A activities have reached $357 billion.
